Showing 1891-1900 of 4063 results for "".
- RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarringhttps://modernod.com/news/rxi-pharmaceuticals-announces-positive-results-from-phase-1-2-trial-with-rxi-109-for-retinal-scarring/2479959/RXi Pharmaceuticals announced positive results with RXI-109 in a phase 1/2 clinical trial. RXI-109-1501 is an open-label, multidose, dose escalation study with three dose cohorts, enrolled sequentially, evaluating the safety and tolerability of RXI-109 injections in the eye of subjects with advan
- Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular Hypertensionhttps://modernod.com/news/nicox-initiates-phase-2-study-of-ncx-470-in-open-angle-glaucoma-and-ocular-hypertension/2479962/Nicox announced the initiation of a phase 2 clinical study evaluating NCX 470, its novel, second-generation nitric oxide (NO)-donating prostaglandin analog, for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension by enrolling 10 patient
- Apellis Pharmaceuticals’ APL-2 Receives FDA Fast Track Designation for the Treatment of Patients with GAhttps://modernod.com/news/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-fda-for-the-treatment-of-patients-with-geographic-atrophy/2479993/Apellis Pharmaceuticals announced that the FDA has granted fast track designation to the company’s APL-2, a novel inhibitor of complement factor C3 as a next generation monotherapy, for the treatment of patients with geographic atrophy (GA). The FDA’s fast track program faci
- Clearside Biomedical Announces Topline Results from Phase 2 Clinical Trial of DME Combination Drughttps://modernod.com/news/clearside-biomedical-announces-positive-topline-results-from-phase-2-clinical-trial-of-dme-combination-drug/2480130/Clearside Biomedical announced positive topline results from its phase 2 clinical trial evaluating suprachoroidal CLS-TA used with intravitreally administered Eylea (aflibercept) in patients with diabetic macular edema (DME) over a 6-month evaluation period, according to a company news release.</
- Isarna Therapeutics Announces Phase 2 Clinical Data Presentations at Upcoming Ophthalmology Conferenceshttps://modernod.com/news/isarna-therapeutics-announces-phase-2-clinical-data-presentations-at-upcoming-ophthalmology-conferences/2482263/Isarna Therapeutics announced upcoming oral presentations at the OIS Retina Innovation Summit on May 4 and the Association for Research in Vision and Ophthalmology (ARVO) meeting on May 7, both in Seattle. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, will present upd
- Trial Highlights 5-Year Performance of 2 Standalone Glaukos iStents vs. Topical Prostaglandinhttps://modernod.com/news/trial-highlights-5-year-performance-of-2-standalone-glaukos-istents-vs-topical-prostaglandin/2476466/Glaukos announced that results of an international glaucoma study published in Ophthalmology Glaucoma showed standalone implantation of two iStent Trabecular Micro-Bypass Stents in newly diagnosed primary open-angle glaucoma (POAG) eyes achieved a 35.3% reduction in mean IOP to 16.5 mmHg
- Valo Health Suspends Development of DR Drug Candidate After Phase 2 Study Resultshttps://modernod.com/news/valo-health-suspends-development-of-dr-drug-candidate-after-phase-2-study-results/2482594/Valo Health announced topline data from its phase 2 SPECTRA study of OPL-0401 in patients with diabetic retinopathy (DR). The study did not meet its primary or secondary endpoints based on the analysis in the prede&sh
- Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in DME Following Interim Analysishttps://modernod.com/news/oxurion-announces-the-continuation-of-kalahari-phase-2-part-b-study-in-dme-following-interim-analysis/2481293/Oxurion NV announced that an Independent Data Monitoring Committee (IDMC) completed its planned interim analysis of the KALAHARI phase 2, Part B clinical trial evaluating Oxurion’s novel plasma kallikrein (PKal) candidate, THR
- Staar Surgical Celebrates 2 Million Lens Milestone for Implantable Collamer Lens (ICL)https://modernod.com/news/staar-surgical-celebrates-2-million-lens-milestone-for-implantable-collamer-lens-icl/2480897/Staar Surgical announced that more than 2 million Visian Implantable Collamer lenses (ICLs) have been sold globally, including more than one and a half million of the company’s latest generation of implantable lenses–EVO Visian ICLs (EVO). New to the U.S. market, E
- EyeCRO Presents Phase 2 Results for MiDROPS Platformhttps://modernod.com/news/eyecro-presents-phase-2-results-for-midrops-platform/2482276/EyeCRO has announced that data from the first clinical application of its MiDROPS (Microemulsion Drug Ocular Penetration System) platform technology was presented by Telios Pharma at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Seattle, WA. The presentation